Advisor Group Holdings, Inc. Spring Works Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

$42.2 Billion
Q3 2024

A detailed history of Advisor Group Holdings, Inc. transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,259 shares of SWTX stock, worth $46,343. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,259

Previous 1,458 13.65%

Holding current value

$46,343

Previous $54,000 25.93%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$32.04 - $42.76 $6,375 - $8,509	-199 Reduced 13.65%	1,259 $40,000
Q2 2024 Aug 13, 2024	SELL	$36.06 - $47.62 $1,189 - $1,571	-33 Reduced 2.21%	1,458 $54,000
Q1 2024 May 10, 2024	SELL	$36.5 - $52.5 $50,041 - $71,977	-1,371 Reduced 47.9%	1,491 $73,000
Q4 2023 Feb 12, 2024	SELL	$18.94 - $37.24 $13,220 - $25,993	-698 Reduced 19.61%	2,862 $104,000
Q3 2023 Nov 13, 2023	BUY	$23.12 - $31.38 $21,987 - $29,842	951 Added 36.45%	3,560 $82,000
Q2 2023 Aug 10, 2023	BUY	$23.15 - $32.71 $18,103 - $25,579	782 Added 42.8%	2,609 $68,000
Q1 2023 May 12, 2023	SELL	$24.97 - $34.05 $1,348 - $1,838	-54 Reduced 2.87%	1,827 $47,000
Q4 2022 Feb 10, 2023	SELL	$21.73 - $28.72 $3,954 - $5,227	-182 Reduced 8.82%	1,881 $48,000
Q3 2022 Nov 14, 2022	BUY	$24.1 - $39.66 $13,881 - $22,844	576 Added 38.74%	2,063 $58,000
Q2 2022 Aug 10, 2022	SELL	$18.36 - $60.07 $936 - $3,063	-51 Reduced 3.32%	1,487 $36,000
Q1 2022 May 04, 2022	BUY	$48.97 - $65.46 $36,384 - $48,636	743 Added 93.46%	1,538 $86,000
Q3 2021 Nov 05, 2021	BUY	$62.66 - $88.26 $33,899 - $47,748	541 Added 212.99%	795 $51,000
Q1 2021 May 13, 2021	BUY	$65.1 - $93.59 $16,535 - $23,771	254 New	254 $19,000

Others Institutions Holding SWTX

# of Institutions

237

Shares Held

68.9M

Call Options Held

144K

Put Options Held

257K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.3B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Spring Works Therapeutics, Inc. Transaction History